The Pediatric Praziquantel Consortium announced new funding last month from Japan’s Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership.

The separate awards—worth a combined $9.3 million—will fund the ADOPT program, dedicated to “wide acceptance and equitable access” for a child-friendly dispersible tablet formulation of schistosomiasis drug praziquantel.

With backers including Astellas, Farmanguinhos and Merck…